MAGNETOFECTION™

Magnetofection™

Description

Magnetofection™ is a novel, simple and highly efficient method to transfect cells in culture. It exploits magnetic force exerted upon gene vectors associated with magnetic particles to draw the vectors towards, possibly even into, the target cells. In this manner, the full vector dose applied gets concentrated on the cells within a few minutes so that 100% of the cells get in contact with a significant vector dose. This has several important consequences:

• Greatly improved transfection rates in terms of percentage of cells transfected compared to standard transfection.
• Up to several thousand fold increased levels of transgene expression compared to standard transfections upon short-term incubation.
• High transfection rates and transgene expression levels are achievable with extremely low vector doses, which allows to save expensive transfection reagents.
• Extremely short process time. A few minutes of incubation of cells with gene vectors are sufficient to generate high transfection efficiency, compared to several hours with standard procedures.

Technology

Magnetofection™ Reagents

As the manufacturer of the Magnetofection™ technology, chemicell offers two types of ready-to-use Magnetofection™ reagents.

PolyMAG is a universally applicable magnetic particle preparation for high efficiency nucleic acid delivery. It is mixed in a one-step procedure with the nucleic acid to be transfected and has been used successfully with plasmid DNA, antisense oligonucleotides and siRNAs.

CombiMAG is a magnetic particle preparation designed to be combined with any commercially available transfection reagent such as polycations and lipids and can be associated with plasmid DNA, antisense oligonucleotides, siRNAs or viruses. It allows you to create your own magnetic gene vector based on your favourite transfection reagent.

Purchaser Notification
The Magnetofection™ reagents and all of its components are developed, designed, intended and sold for research use only. They are not to be used for human diagnostic or any drug intended.
Magnetofection™ are registered trademark

Nucleic Acids Dose Response and Transfection Kinetics

Applications

Magnetofection™ is generally applicable for adherent cells and has been tested with a variety of immortalized cell lines and primary cells listed below. If a particular cell type or cell line is not listed this does not mean that Magnetofection™ would not work. Also for the cells listed, some reagents have not been tested so far, as indicated by "n.d." (not determined).

The CombiMAG reagent can be combined with any polycationic and lipidic transfection reagent, and also with adenoviral and retroviral vectors. In some cases, references are made in the footnotes to very successful combinations with commercially available reagents that have been tested so far.

Type of nucleic acid / virus	PolyMAG	CombiMAG
Plasmid DNA
Antisense Oligonucleotides
siRNA
Adenovirus	n.d.
Retrovirus	n.d.

Effectene (Qiagen)

Effectene + CombiMAG

Primary human umbilical vein endothelial cells positioned on the MagnetoFACTOR plate were incubated for 15 min with a Cy3 fluorescencelabeled antisense-oligonucleotide complexed with Effectene™ (Qiagen; left) or Effectene™ + CombiMAG (right).

(Data kindly provided by F. Kroetz. Ludwig-Maximilians University Munich)

Adherent cells
Cell Line	Cell Type	Source	PolyMAG	CombiMAG*
HeLa	cervix carcinoma	human	+	+
HEK 293	kidney	human	+	+
BHK	kidney	hamster	n.d.	+
CHO	ovarian	hamster	+	+
NIH 3T3	fibroblasts	mouse	+	+
16HB140	airway epithelium	human	+	n.d.
EJ28	bladder cancer	human	+	n.d.
HBL-100	breast	human	n.d.	+
MCF7	breast adenocarcinoma	human	+	+
MCS7	breast adenocarcinoma	human	+	n.d.
HeLa	cervix carcinoma	human	+	+
HCT 116	colon adenocarcinoma	human	n.d.	+
SW480	colon adenocarcinoma	human	n.d.	+
LoVo	colon adenocarcinoma	human	n.d.	+
HCT15	colon adenocarcinoma	human	n.d.	+
A431	epidermoid carcinoma	human	n.d.	+
HT-1080	fibrosarcoma	human	+	n.d.
HFF	foreskin fibroblast	human	+	+
Hep G2	hepatocellular carcinoma	human	+	+
HaCat	keratinocytes	human	n.d.	+
293 T	kidney	human	+	+
293 T-17	kidney	human	n.d.	+
HEK 293	kidney	human	+	+
SK-MES-1	lung carcinoma	human	+	n.d.
MRC 5	lung, embryonic	human	+	+
MeWo	melanoma	human	n.d.	+
SK-MEL-28	melanoma	human	n.d.	+
SHSY-5Y	neuroblastoma	human	n.d.	+
A549	Non-small cell lung carcinoma	human	n.d.	+
SaOS-2	osteo sarcoma	human	n.d.	+
BTK-143	osteo sarcoma	human	n.d.	+
181RDB	pancreatic	human	n.d.	+
PC-3	prostate carcinoma	human	n.d.	+
HSG	salivary gland, submandibular	human	n.d.	+
NCI H-82	small cell lung cancer	human	+	n.d.
ECV-304	urinary bladder carcinoma	human	n.d.	+
CT-26	colon carcinoma	mouse	+	n.d.
F9	embryonal carcinoma	mouse	+	n.d.
L929	fibroblast, connective tissue	mouse	+	n.d.
MEF	fibroblast	mouse	+	n.d.
NIH 3T3	fibroblasts	mouse	+	+
HT-22	hippocampal neuroblast	mouse	n.d.	+
mIC-(cl2)	intestine	mouse	n.d.	+
B16F10	melanoma	mouse	+	n.d.
B16F10.9	melanoma	mouse	+	n.d.
N2a	neuroblastoma	mouse	+	n.d.
NS20Y	neuroblastoma	mouse	n.d.	+
SM 10	trophoblast	mouse	n.d.	+
PC12	adrenal pheochromocytoma	rat	+	n.d.
PC6-3	daughter cell line of PC12	rat	+	n.d.
C6	glioma	rat	n.d.	+
H4IIE	hepatoma	rat	n.d.	+
L6	skeletal muscle cell	rat	+	n.d.
RV	vein	rat	+	n.d.
COS-7	kidney	monkey	+	+
CV-1	kidney	monkey	+	n.d.
COS-1	kidney	monkey	n.d.	+
Vero 76	kidney	monkey	n.d.	+
BHK	kidney	hamster	n.d.	+
V79	lung fibroblasts	hamster	+	n.d.
CHO	ovarian	hamster	+	+
PT-11	kidney	bovine	n.d.	+
MDCK	kidney	canine	+	n.d.
CRFK	kidney	cat	n.d.	+
VSa13	bone (chondrocyte-like)	fish	+	n.d.
AM-C6SC8	kidney	pig	n.d.	+
-	fibroblasts	xenopus	+	n.d.
EMC	mesenthelial. Cells (epicard)		n.d.	+
Suspension cells
Cell Line	Cell Type	Source	PolyMAG	CombiMAG*
THP-1	acute myeloid leukemia	human	n.d.	+
Jurkat	acute T-cell lymphoma	human	n.d.	+
BL-41	B-cell lymphoma	human	+	n.d.
K562	chronic myeloid lymphoma	human	n.d.	+
P815	mastocytoma	mouse	n.d.	+
U937	histiocytic lymphoma	human	+	+
Primary cells
Cell Line	Cell Type	Source	PolyMAG	CombiMAG*
	aortic endothelial cells	human	+	n.d.
	epithelial (HUVEC)	human	+	n.d.
	fibroblasts	human	+	+
	fibroblasts, diploid	human	+	+
	gastric gland	human	+	+
	glioma	human	+	n.d.
	keratinocytes	human	n.d.	+
	LNCaP	human	n.d.	+
	mammal epithelium	human	n.d.	+
	nasal airway epithelium	human	+	n.d.
	pancreatic tumor	human	+	n.d.
	peripheral blood lymphocytes	human	+	+
	stroma cells (endometrium)	human	n.d.	+
	T-cells	human	+	n.d.
	trophoblastic cells	human	n.d.	+
	fibroblasts (MEF)	mouse	n.d.	+
	hippocampal neurons	mouse	+	+
	neurons	mouse	+	n.d.
	peripheral blood lymphocytes	mouse	n.d.	+
	T-cells	mouse	+	n.d.
	hepatocytes	rat	n.d.	+
	neurons (E18.5)	rat	+	n.d.
	aortic endothelial cells	bovine	+	n.d.
	carotid artery smooth muscle	bovine	+	n.d.
	chromaffine cells	bovine	n.d.	+
	lens	bovine	+	n.d.
	airway epithelium	pig	n.d.	+
	chondrocytes	pig	+	+
	fibrochondrocytes	pig	+	+
	pSM, smooth muscle	pig	n.d.	+

^* Corresponds to successfully transfected by CombiMAG in association with different commercial transfection reagents such as FuGENE™ (Roche), Lipofectamine™, METAFECTENE™ (Biontex GmbH) and DMRIE-C™ (Invitrogen); adenovirus; Effectene™ (Qiagen)

n.d. = not determined

Available Kits

Product Number	Description	Size (sufficient for n µg DNA)	Number of transfections (96-well format)	Price Euro / US$
9001	PolyMAG-100	100	1000	95 / 125
9002	PolyMAG-500	500	5000	365 / 480
9003	PolyMAG-1000	1000	10000	665 / 875
9004	CombiMAG-100	100	500	50 / 65
9005	CombiMAG-500	500	2500	180 / 235
9006	CombiMAG-1000	1000	5000	350 / 460
9007	MagnetoFACTOR plate 96			350 / 460
9009	MagnetoFACTOR plate 24			350 / 460
9008	SPECIAL OFFER: MagnetoFACTOR plate PolyMAG-200 CombiMAG-200	200 200	2000 1000	350 / 460

Storage:
All components of the Magnetofection™ kit should be stored at room temperatur (20-25°C). After first use store the kit at +4°C.

Do not freeze the magnetic nanoparticles
Do not add anything to the stock solution of magnetic nanoparticles
Shipping Conditions: Room Temperatur

SPECIAL OFFER

As an introductory offer you will receive one vial each of PolyMAG and CombiMAG sufficient for 200 µg of DNA each for free in combination with the purchase of the MagnetoFACTOR plate. This will enable you to optimize your Magnetofection™ in up to 3000 transfection experiments (96-well format).